91 related articles for article (PubMed ID: 20672820)
1. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
Arhancet GB; Woodard SS; Iyanar K; Case BL; Woerndle R; Dietz JD; Garland DJ; Collins JT; Payne MA; Blinn JR; Pomposiello SI; Hu X; Heron MI; Huang HC; Lee LF
J Med Chem; 2010 Aug; 53(16):5970-8. PubMed ID: 20672820
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Meyers MJ; Arhancet GB; Hockerman SL; Chen X; Long SA; Mahoney MW; Rico JR; Garland DJ; Blinn JR; Collins JT; Yang S; Huang HC; McGee KF; Wendling JM; Dietz JD; Payne MA; Homer BL; Heron MI; Reitz DB; Hu X
J Med Chem; 2010 Aug; 53(16):5979-6002. PubMed ID: 20672822
[TBL] [Abstract][Full Text] [Related]
3. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
[TBL] [Abstract][Full Text] [Related]
4. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Matsunaga N; Ora T; Ohyabu N; Nishigaki N; Imura Y; Igata Y; Matsui H; Motoyaji T; Tanaka T; Habuka N; Sogabe S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
J Med Chem; 2011 Dec; 54(24):8616-31. PubMed ID: 22074142
[TBL] [Abstract][Full Text] [Related]
5. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
6. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Bolli MH; Marfurt J; Grisostomi C; Boss C; Binkert C; Hess P; Treiber A; Thorin E; Morrison K; Buchmann S; Bur D; Ramuz H; Clozel M; Fischli W; Weller T
J Med Chem; 2004 May; 47(11):2776-95. PubMed ID: 15139756
[TBL] [Abstract][Full Text] [Related]
7. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
[TBL] [Abstract][Full Text] [Related]
8. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
Poon SF; Eastman BW; Chapman DF; Chung J; Cramer M; Holtz G; Cosford ND; Smith ND
Bioorg Med Chem Lett; 2004 Nov; 14(22):5477-80. PubMed ID: 15482907
[TBL] [Abstract][Full Text] [Related]
9. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
Pei Z; Li X; Longenecker K; von Geldern TW; Wiedeman PE; Lubben TH; Zinker BA; Stewart K; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Long M; Wells H; Kempf-Grote AJ; Madar DJ; McDermott TS; Bhagavatula L; Fickes MG; Pireh D; Solomon LR; Lake MR; Edalji R; Fry EH; Sham HL; Trevillyan JM
J Med Chem; 2006 Jun; 49(12):3520-35. PubMed ID: 16759095
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5.
Burdi DF; Hunt R; Fan L; Hu T; Wang J; Guo Z; Huang Z; Wu C; Hardy L; Detheux M; Orsini MA; Quinton MS; Lew R; Spear K
J Med Chem; 2010 Oct; 53(19):7107-18. PubMed ID: 20809633
[TBL] [Abstract][Full Text] [Related]
12. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger RA; Cui H; Dowdell SE; Franz RG; Gaitanopoulos DE; Goodman KB; Hilfiker MA; Ivy RL; Leber JD; Marino JP; Oh HJ; Viet AQ; Xu W; Ye G; Zhang D; Zhao Y; Jolivette LJ; Head MS; Semus SF; Elkins PA; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Doe CP; Bentley R; Chen ZX; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):2-5. PubMed ID: 17201404
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
14. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Biswas K; Li A; Chen JJ; D'Amico DC; Fotsch C; Han N; Human J; Liu Q; Norman MH; Riahi B; Yuan C; Suzuki H; Mareska DA; Zhan J; Clarke DE; Toro A; Groneberg RD; Burgess LE; Lester-Zeiner D; Biddlecome G; Manning BH; Arik L; Dong H; Huang M; Kamassah A; Loeloff R; Sun H; Hsieh FY; Kumar G; Ng GY; Hungate RW; Askew BC; Johnson E
J Med Chem; 2007 May; 50(9):2200-12. PubMed ID: 17408249
[TBL] [Abstract][Full Text] [Related]
15. Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.
Almansa C; Gómez LA; Cavalcanti FL; de Arriba AF; Rodríguez R; Carceller E; García-Rafanell J; Forn J
J Med Chem; 1996 May; 39(11):2197-206. PubMed ID: 8667363
[TBL] [Abstract][Full Text] [Related]
16. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Casimiro-Garcia A; Piotrowski DW; Ambler C; Arhancet GB; Banker ME; Banks T; Boustany-Kari CM; Cai C; Chen X; Eudy R; Hepworth D; Hulford CA; Jennings SM; Loria PM; Meyers MJ; Petersen DN; Raheja NK; Sammons M; She L; Song K; Vrieze D; Wei L
J Med Chem; 2014 May; 57(10):4273-88. PubMed ID: 24738581
[TBL] [Abstract][Full Text] [Related]
17. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Hartz RA; Ahuja VT; Zhuo X; Mattson RJ; Denhart DJ; Deskus JA; Vrudhula VM; Pan S; Ditta JL; Shu YZ; Grace JE; Lentz KA; Lelas S; Li YW; Molski TF; Krishnananthan S; Wong H; Qian-Cutrone J; Schartman R; Denton R; Lodge NJ; Zaczek R; Macor JE; Bronson JJ
J Med Chem; 2009 Dec; 52(23):7653-68. PubMed ID: 19954247
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
[TBL] [Abstract][Full Text] [Related]
19. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.
Ward SE; Harries M; Aldegheri L; Andreotti D; Ballantine S; Bax BD; Harris AJ; Harker AJ; Lund J; Melarange R; Mingardi A; Mookherjee C; Mosley J; Neve M; Oliosi B; Profeta R; Smith KJ; Smith PW; Spada S; Thewlis KM; Yusaf SP
J Med Chem; 2010 Aug; 53(15):5801-12. PubMed ID: 20614889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
